SNDX Stock Overview
A clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Syndax Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.66 |
| 52 Week High | US$25.34 |
| 52 Week Low | US$11.22 |
| Beta | 1.01 |
| 1 Month Change | -0.67% |
| 3 Month Change | -7.06% |
| 1 Year Change | -5.66% |
| 3 Year Change | 17.45% |
| 5 Year Change | 183.79% |
| Change since IPO | 72.02% |
Recent News & Updates
Recent updates
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Mar 28Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Mar 04
Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?
Nov 20Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Sep 27Syndax Pharmaceuticals Q2 2022 Earnings Preview
Aug 07Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
Apr 08Is Syndax Pharmaceuticals (NASDAQ:SNDX) Weighed On By Its Debt Load?
Jun 11Shareholders Would Not Be Objecting To Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) CEO Compensation And Here's Why
May 07The Syndax Pharmaceuticals (NASDAQ:SNDX) Share Price Has Gained 150%, So Why Not Pay It Some Attention?
Mar 15Shareholder Returns
| SNDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | 0.7% | 1.2% |
| 1Y | -5.7% | 5.0% | 27.7% |
Return vs Industry: SNDX underperformed the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: SNDX underperformed the US Market which returned 26% over the past year.
Price Volatility
| SNDX volatility | |
|---|---|
| SNDX Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SNDX has not had significant price volatility in the past 3 months.
Volatility Over Time: SNDX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 184 | Michael Metzger | www.syndax.com |
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat.
Syndax Pharmaceuticals, Inc. Fundamentals Summary
| SNDX fundamental statistics | |
|---|---|
| Market cap | US$1.72b |
| Earnings (TTM) | -US$240.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.3x
P/E RatioIs SNDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNDX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$240.63m |
| Earnings | -US$240.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.83 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNDX perform over the long term?
See historical performance and comparison